F2G Ltd Announces the Acceptance of F901318 to Participate in the EMA’s Adaptive Pathways Pilot Programme
F2G Ltd, a UK based antifungal drug discovery and development company, today announced that its novel systemic antifungal product F901318 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways pilot programme. Initiated in March 2014, the Adaptive... - December 03, 2015
F2G Limited, the UK-Based Antifungal Drug Discovery and Development Company, Announces a Major Funding Award from the Technology Strategy Board’s Biomedical Catalyst
F2G Limited, the UK-based antifungal drug discovery and development company, today announced a major funding award from the Technology Strategy Board’s Biomedical Catalyst. - September 11, 2014
F2G Ltd, the UK Antifungal Drug Discovery & Development Company, Today Announces Commencement of a Phase 1 Single Ascending Dose Study of a Novel Antifungal Agent
F2G Limited, the antifungal research and development company today announced a major milestone in the development of its novel IV/oral systemic antifungal (F901318) with the commencement of a Phase I clinical study. This study initiates the IV Phase I clinical development of F901318 with the oral... - September 04, 2014
F2G Ltd and the University of Manchester Announce a New 6.1 Million Euro Project to Develop New Antifungal Agents to Treat Resistant Fungal Infections.
F2G Ltd, a privately-held antifungal drug discovery and development company and The University of Manchester, today announced the commencement of a 6.1 million euro EU-funded project to discover and develop novel antifungal drugs to treat serious, life-threatening fungal infections. The NOFUN... - June 28, 2013
F2G Ltd Appoints Ian Nicholson as Chief Executive Officer
F2G Ltd, the UK-based antifungal drug discovery and development company, today announced the appointment of Ian Nicholson to the position of CEO and to the Board of Directors. - March 20, 2013
F2G Ltd Announces the Appointment of Michael R. Hodges, M.D. to the Board of Directors
F2G Limited, the UK based antifungal drug discovery and development company, today announced the appointment of Dr Michael R. Hodges to the Company’s Board of Directors. Michael R Hodges, M.D., BSc., MRCP (UK) has 20 years of biopharmaceutical development experience and has worked in both... - September 13, 2010